Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;27(7):4011-4016.
doi: 10.1111/dom.16415. Epub 2025 Apr 28.

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study

Frank Snoek  1 , Gagik Galstyan  2 , Niaz Khan  3 , Amir Tirosh  4 , Jothydev Kesavadev  5 , Hernando Vargas-Uricoechea  6 , Houssem Baghous  7 , Maria Aileen Mabunay  8 , Natasa Grulovic  9 , Valerie Corp Dit Genti  9 , Jerome Msihid  10 , Stewart Harris  11
Affiliations

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study

Frank Snoek et al. Diabetes Obes Metab. 2025 Jul.
No abstract available

Keywords: Gla‐300; patient‐reported outcomes; treatment satisfaction; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

FS received research funding (to institute) from Novo Nordisk and Sanofi and was a consultant/speaker for Abbott, Almirall, Sanofi, Lilly and Roche. MAM, NG, VCG and JM are employees of Sanofi and may hold shares and/or stock options in the company. AT, HV‐U, NK and GG were members of the ATOS Steering Committee and received honoraria in relation to ATOS. AT is a member of the National Diabetes Council and Head of the Diabetes Committee of the Israeli Endocrine Society and has received honoraria from Sanofi; a grant from Medtronic; consulting fees from Sanofi, Novo Nordisk, MSD, Merck, AstraZeneca, Medtronic and Dreamed Diabetes; and personal fees for participation in advisory boards from Sanofi, Novo Nordisk, MSD, Merck, AstraZeneca and Bayer. JK has no conflicts of interest. HV‐U received honoraria from Sanofi and Abbott and personal fees for participation in advisory boards and funding for attending meetings/travel from Sanofi. SH received research funding from BI, Novo Nordisk, Novartis and Eli Lilly and is a consultant/speaker for Abbott, Bayer, Dexcom, Eli Lilly, Novo Nordisk and Sanofi. HB is a consultant/speaker for Novo Nordisk, Sanofi and Lilly.

Figures

FIGURE 1
FIGURE 1
Treatment satisfaction results according to improvement in DTSQs at month 12. The percentage of participants achieving clinically meaningful change—evaluable population (N = 3656). n, number of participants. DTSQs improvers are participants for whom the treatment satisfaction total score improvement is ≥4 points (i.e. 0.5 × SD of baseline DTSQs total score) from baseline. CI, confidence interval; DTSQs, Diabetes Treatment Satisfaction Questionnaire status version; SD, standard deviation.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022;45(11):2753‐2786. - PMC - PubMed
    1. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real‐world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30(5):512‐524. - PubMed
    1. Evans M, Engberg S, Faurby M, Fernandes J, Hudson P, Polonsky W. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review. Diabetes Obes Metab. 2022;24(3):377‐390. - PMC - PubMed
    1. Sarbacker GB, Urteaga EM. Adherence to insulin therapy. Diabetes Spectr. 2016;29(3):166‐170. - PMC - PubMed
    1. Kostev K, Dippel FW, Rathmann W. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care. Prim Care Diabetes. 2016;10(2):142‐147. - PubMed

Grants and funding

LinkOut - more resources